Literature DB >> 23271293

Preliminary evaluation of safety of conditionally replication adenovirus M4.

Caihong Chen1,2, Haiyan Fang1, Yumei Rao1,3, Peng Wu1, Yang He1, Ding Ma1, Qinglei Gao4.   

Abstract

Conditionally replication adenovirus M4, which was constructed in our lab, was proved to have good clinical application prospect for its good anti-tumor and anti-metastasis effect. However, clinically applying M4 faces many problems. One of the most important is the safety of M4. In this study, we investigated the safety of M4 by comparing with Adv-TK, which was proved to be safe in I-III phase clinical trials. M4 and Adv-TK were injected into mice via the tail vein separately, and the mice were sacrificed at the indicated time. Blood was collected for biochemical tests, the liver was harvested for hematoxylin and eosin (H&E) staining and viral quantification, and splenic lymphocytes were separated for adenovirus specific cellular immune response. Our results showed that M4 had no obvious effect on mouse general symptoms. A transient reversible infiltration of inflammatory cells in collect abbacy was only observed in M4 group, and a transient slight increase in Cr level was detected both after M4 and Adv-TK injection. The adenovirus specific cellular immune response induced by M4 was similar to that by Adv-TK, and the distribution and metabolism of M4 in the mouse liver were also similar to those of Adv-TK. It was concluded that conditionally replication adenovirus M4 had the same safety as Adv-TK. The study provides safety basis for the coming clinical trials of M4.

Entities:  

Mesh:

Year:  2012        PMID: 23271293     DOI: 10.1007/s11596-012-1054-y

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  24 in total

Review 1.  Targeted adenovirus vectors.

Authors:  Hiroyuki Mizuguchi; Takao Hayakawa
Journal:  Hum Gene Ther       Date:  2004-11       Impact factor: 5.695

2.  Identifying the safety profile of a novel infectivity-enhanced conditionally replicative adenovirus, Ad5-delta24-RGD, in anticipation of a phase I trial for recurrent ovarian cancer.

Authors:  John G Page; Baohong Tian; Karen Schweikart; Joseph Tomaszewski; Ray Harris; Trevor Broadt; Judith Polley-Nelson; Patricia E Noker; Minghui Wang; Sharmila Makhija; Rose Aurigemma; David T Curiel; Ronald D Alvarez
Journal:  Am J Obstet Gynecol       Date:  2007-04       Impact factor: 8.661

3.  Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors.

Authors:  T Kusaba; T Nakayama; K Yamazumi; Y Yakata; A Yoshizaki; T Nagayasu; I Sekine
Journal:  J Clin Pathol       Date:  2005-08       Impact factor: 3.411

4.  Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells.

Authors:  Linda B Mora; Ralf Buettner; John Seigne; Jose Diaz; Nazeel Ahmad; Roy Garcia; Tammy Bowman; Robert Falcone; Rita Fairclough; Alan Cantor; Carlos Muro-Cacho; Sandy Livingston; James Karras; Julio Pow-Sang; Richard Jove
Journal:  Cancer Res       Date:  2002-11-15       Impact factor: 12.701

5.  Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

Authors:  Srdan Verstovsek; Hagop Kantarjian; Ruben A Mesa; Animesh D Pardanani; Jorge Cortes-Franco; Deborah A Thomas; Zeev Estrov; Jordan S Fridman; Edward C Bradley; Susan Erickson-Viitanen; Kris Vaddi; Richard Levy; Ayalew Tefferi
Journal:  N Engl J Med       Date:  2010-09-16       Impact factor: 91.245

6.  A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy.

Authors:  T L DeWeese; H van der Poel; S Li; B Mikhak; R Drew; M Goemann; U Hamper; R DeJong; N Detorie; R Rodriguez; T Haulk; A M DeMarzo; S Piantadosi; D C Yu; Y Chen; D R Henderson; M A Carducci; W G Nelson; J W Simons
Journal:  Cancer Res       Date:  2001-10-15       Impact factor: 12.701

7.  Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.

Authors:  Fabio P S Santos; Hagop M Kantarjian; Nitin Jain; Taghi Manshouri; Deborah A Thomas; Guillermo Garcia-Manero; Debra Kennedy; Zeev Estrov; Jorge Cortes; Srdan Verstovsek
Journal:  Blood       Date:  2009-12-11       Impact factor: 22.113

8.  Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies.

Authors:  Della Makower; Alla Rozenblit; Howard Kaufman; Morris Edelman; Maureen E Lane; James Zwiebel; Hilda Haynes; Scott Wadler
Journal:  Clin Cancer Res       Date:  2003-02       Impact factor: 12.531

Review 9.  The influence of innate and pre-existing immunity on adenovirus therapy.

Authors:  Anne K Zaiss; Hidevaldo B Machado; Harvey R Herschman
Journal:  J Cell Biochem       Date:  2009-11-01       Impact factor: 4.429

10.  Toxicology profiles of a novel p53-armed replication-competent oncolytic adenovirus in rodents, felids, and nonhuman primates.

Authors:  Changqing Su; Hui Cao; Shuping Tan; Yao Huang; Xiaoyuan Jia; Lixin Jiang; Kai Wang; Ying Chen; Ju Long; Xinyuan Liu; Mengchao Wu; Xiaobing Wu; Qijun Qian
Journal:  Toxicol Sci       Date:  2008-08-14       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.